Bharat Biotech International Ltd
Show jobs for this employer
31 articles with Bharat Biotech International Ltd
-
The Pennsylvania-based eye disease company had to change its application from an Emergency Use Authorization to a full BLA approval.
-
Bharat will conduct Phase IV studies to check real-world efficacy against the virus, while Ocugen says Covaxin will be a valuable tool in helping to end the COVID-19 pandemic.
-
Ocugen Expands COVAXIN™ Commercialization Rights to Include Canada
6/3/2021
Ocugen to have exclusive co-development, manufacturing, and commercialization rights to COVAXIN™ in Canada, in addition to its existing US rights
-
Ocugen submitted a “Master File” to the U.S. FDA for COVAXIN, the vaccine that has already received authorization in India for people ages 12 and above.
-
India's Double Mutant Strain Raises Concern, But Companies Confident on Vaccine Effectiveness
4/30/2021
A study found in India that the existing COVID-19 vaccines should be effective against the Indian variant, not just the Pfizer-BioNTech vaccine. -
2021 COVID-19 News: COVID-19 Possible Spread in Vehicles, US to Share AZ's COVID-19 Vaccine Globa...
4/27/2021
Please check out the biopharma industry's COVID-19 stories that are trending for April 27, 2021. -
A new study published online has provided some hope for the citizens in India, with researchers suggesting that the Covaxin vaccine, developed by Bharat Biotech and Pennsylvania-based Ocugen, could neutralize the SARS-CoV-2 variant leading the second wave in the country.
-
Ocugen’s plan to bring a COVID-19 vaccine developed by India-based Bharat Biotech later this year remains on track following an interim analysis of Phase III data that shows the vaccine demonstrated a 78% efficacy against mild to moderate infection and 100% efficacy against severe COVID-19.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 9, 2021.
-
Days after vaccine-maker Bharat Biotech released interim Phase III efficacy data for a COVID-19 vaccine already in use in India, a pulmonary expert is expressing enthusiasm for the company’s next-generation intranasal vaccine on track to enter clinical testing this quarter.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 16, 2021.
-
Clinical Catch-Up: December 14-18
12/21/2020
Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look. -
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 1, 2020.
-
Bharat Biotech, Thomas Jefferson University pursue a promising vaccine candidate against COVID-19
5/20/2020
The vector used in this new COVID-19 vaccine under accelerated development program is a deactivated rabies vaccine that is known to produce a strong immune response, and is approved for the whole population including children and pregnant women.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 20, 2020.
-
Bharat Biotech Says Working On Two Possible Zika Vaccines
2/3/2016
-
Bharat Biotech Vaccine Doses Touch 1 Billion
2/4/2010
-
Bharat Biotech Begins Phase I Clinical Trials of HN-VAC - its Cell Culture H1N1 Vaccine
1/22/2010
-
Bharat Biotech's Rabies Vaccine ‘INDIRAB(R)’ Sales Crosses 10 Million Doses; Sales Expected to Double in Coming Years as Demand Increases in Developing World
10/28/2009
-
Bharat Biotech Inks Pact with Orissa Govt to set up Rs 100 cr ‘Konark Knowledge Park’
10/27/2009